Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIQ


Primary Symbol: IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc > Q1 updates IMV
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by Jthom376on Mar 05, 2021 10:31am
201 Views
Post# 32727418

Q1 updates IMV

Q1 updates IMVCurious on people's thoughts, maybe because there has been a lot of let downs with this investment.... Ovarian update in Q 4, I saw as very good, yet little impact on stock. DLBCL also was very good, but little mpact on stock. Does anyone see these upcoming releases to be bigger than what came out Q4 2020? Basket trial seems like a midway update per their presentation. DLBCL, seems like a FDA update on next steps... bio marker on ovarian maybe an attention getter IF it's matches the previous Q4 bio marker update... Merck deal... would need to be a big investment...

I see it all coming down to Merck for this round... anyone else? I've watched this page for a year now... appreciate everyone's opinion. This investment has been painful... seems good news just doesn't have the impact on this like it has on others. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities